Osteopore Ltd (OSX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Osteopore Ltd (OSX) has a cash flow conversion efficiency ratio of 0.739x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.28 Million ≈ $-903.25K USD) by net assets (AU$-1.73 Million ≈ $-1.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Osteopore Ltd (OSX) balance sheet quality index to measure how much of total assets are equity-financed.
Osteopore Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Osteopore Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Osteopore Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Osteopore Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Osteopore Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kiplin Metals Inc
V:KIP
|
-0.072x |
|
Cynata Therapeutics Ltd
AU:CYP
|
-0.969x |
|
Sure-Tech Investments LP
TA:STEC
|
-0.038x |
|
Treatt PLC
LSE:TET
|
0.018x |
|
Hexima Ltd
AU:HXL
|
-0.081x |
|
Cascadero Copper Corp
V:CCD
|
0.082x |
|
Grosvenor Resource Corp
V:GVR
|
-0.811x |
|
Kneomedia Ltd
AU:KNM
|
0.057x |
Annual Cash Flow Conversion Efficiency for Osteopore Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Osteopore Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Osteopore Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | AU$-1.73 Million ≈ $-1.22 Million |
AU$-2.56 Million ≈ $-1.81 Million |
1.481x | +114.69% |
| 2024-12-31 | AU$306.22K ≈ $216.67K |
AU$-3.09 Million ≈ $-2.18 Million |
-10.084x | -16.73% |
| 2023-12-31 | AU$432.60K ≈ $306.09K |
AU$-3.74 Million ≈ $-2.64 Million |
-8.639x | -355.31% |
| 2022-12-31 | AU$2.11 Million ≈ $1.49 Million |
AU$-4.00 Million ≈ $-2.83 Million |
-1.897x | -167.87% |
| 2021-12-31 | AU$5.37 Million ≈ $3.80 Million |
AU$-3.81 Million ≈ $-2.69 Million |
-0.708x | -262.52% |
| 2020-12-31 | AU$9.00 Million ≈ $6.37 Million |
AU$-1.76 Million ≈ $-1.24 Million |
-0.195x | +66.85% |
| 2019-12-31 | AU$2.97 Million ≈ $2.10 Million |
AU$-1.75 Million ≈ $-1.24 Million |
-0.589x | -646.63% |
| 2018-12-31 | AU$4.23 Million ≈ $3.00 Million |
AU$-334.12K ≈ $-236.41K |
-0.079x | -1197.74% |
| 2017-12-31 | AU$-1.84 Million ≈ $-1.30 Million |
AU$11.16K ≈ $7.90K |
-0.006x | -104.48% |
| 2016-12-31 | AU$-1.36 Million ≈ $-959.71K |
AU$-184.27K ≈ $-130.38K |
0.136x | -- |
About Osteopore Ltd
Osteopore Limited, a regenerative medicine company, engages in the production of 3D-printed biomimetic and bioresorbable implants in Vietnam, South Korea, the Philippines, Singapore, India, Taiwan, Indonesia, the Netherlands, United Arab Emirates, Australia, and internationally. The company commercializes products designed to enable natural bone healing across multiple therapeutic areas. Its tech… Read more